ES2190205T3 - Combinacion para el tratamiento de la dependencia del alcohol que contiene un antagonista opioide y un modulador del complejo receptor de nmda. - Google Patents

Combinacion para el tratamiento de la dependencia del alcohol que contiene un antagonista opioide y un modulador del complejo receptor de nmda.

Info

Publication number
ES2190205T3
ES2190205T3 ES99916907T ES99916907T ES2190205T3 ES 2190205 T3 ES2190205 T3 ES 2190205T3 ES 99916907 T ES99916907 T ES 99916907T ES 99916907 T ES99916907 T ES 99916907T ES 2190205 T3 ES2190205 T3 ES 2190205T3
Authority
ES
Spain
Prior art keywords
treatment
nmda receptor
receptor complex
combination
opioid antagonist
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES99916907T
Other languages
English (en)
Inventor
Martine Daoust
Yves Le Buclay Bonhomme
Philippe Durbin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sante SAS
Original Assignee
Merck Sante SAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sante SAS filed Critical Merck Sante SAS
Application granted granted Critical
Publication of ES2190205T3 publication Critical patent/ES2190205T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse

Abstract

Uso de una combinación sinérgica de: (i) un antagonista opioide, y (ii) un modulador del complejo receptor NMDA, para la preparación de una composición farmacéutica para el tratamiento de la dependencia del alcohol.
ES99916907T 1998-03-26 1999-03-26 Combinacion para el tratamiento de la dependencia del alcohol que contiene un antagonista opioide y un modulador del complejo receptor de nmda. Expired - Lifetime ES2190205T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP98400723A EP0945133A1 (en) 1998-03-26 1998-03-26 Combination for the treatment of alcohol and drug dependence containing an opioid antagonist and a NMDA receptor complex modulator

Publications (1)

Publication Number Publication Date
ES2190205T3 true ES2190205T3 (es) 2003-07-16

Family

ID=8235311

Family Applications (1)

Application Number Title Priority Date Filing Date
ES99916907T Expired - Lifetime ES2190205T3 (es) 1998-03-26 1999-03-26 Combinacion para el tratamiento de la dependencia del alcohol que contiene un antagonista opioide y un modulador del complejo receptor de nmda.

Country Status (18)

Country Link
US (1) US6512009B1 (es)
EP (2) EP0945133A1 (es)
KR (1) KR20010034678A (es)
AT (1) ATE230993T1 (es)
AU (1) AU758569B2 (es)
BR (1) BR9909138A (es)
CA (1) CA2325739C (es)
CZ (1) CZ296367B6 (es)
DE (1) DE69904922T2 (es)
DK (1) DK1063995T3 (es)
ES (1) ES2190205T3 (es)
HK (1) HK1032542A1 (es)
HU (1) HU226555B1 (es)
NO (1) NO319313B1 (es)
PL (1) PL193241B1 (es)
RU (1) RU2226107C2 (es)
SK (1) SK284623B6 (es)
WO (1) WO1999048500A1 (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8052982B2 (en) 1998-07-20 2011-11-08 Peptech Animal Health Pty Limited Bioimplant formulation comprising lecithin and stearin
EP1104296B1 (en) * 1998-07-20 2012-06-13 Peptech Animal Health Pty Limited Bioimplant formulation
WO2001052851A1 (en) * 2000-01-22 2001-07-26 Albert Shulman Methods for the treatment of substance abuse
EP1262196A3 (en) * 2001-05-23 2002-12-18 Pfizer Products Inc. Combination of a monoamine reuptake inhibitor and an opioid antagonist for use in alcoholism and alcohol dependence
DE10129265A1 (de) * 2001-06-18 2003-01-02 Hf Arzneimittelforsch Gmbh Wirkstoff-Kombination zur medikamentösen Sucht- oder Rauschmitteltherapie
ES2187288B1 (es) * 2001-09-24 2004-09-16 Garbil Pharma Investigacion Chile Ltda Aminas como agentes anti-alcoholismo.
EP1509182A4 (en) * 2002-05-31 2009-12-30 Titan Pharmaceuticals Inc IMPLANTABLE POLYMERS DEVICE FOR THE DELAYED RELEASE OF BUPRENORPHINE
EP2218448B1 (en) 2002-12-13 2015-09-23 Durect Corporation Oral drug delivery system comprising high viscosity liquid carrier materials
CA2510465A1 (en) * 2002-12-18 2004-07-08 Pain Therapeutics Oral dosage forms with therapeutically active agents in controlled release cores and immediate release gelatin capsule coats
AU2004228017C1 (en) * 2003-03-31 2010-06-03 Titan Pharmaceuticals, Inc. Implantable polymeric device for sustained release of dopamine agonist
CA2526101A1 (en) * 2003-05-30 2004-12-23 Titan Pharmaceuticals, Inc. Implantable polymeric device for sustained release of nalmefene
US20070099947A1 (en) * 2005-11-03 2007-05-03 Alkermes, Inc. Methods and compositions for the treatment of brain reward system disorders by combination therapy
CA2673481A1 (en) * 2006-12-19 2008-06-26 University Of Virginia Patent Foundation Combined effects of topiramate and ondansetron on alcohol consumption
JP2011506319A (ja) 2007-12-06 2011-03-03 デュレクト コーポレーション 疼痛、関節炎症状、または慢性疾患に伴う炎症の治療に有用な方法
CN102016571A (zh) 2008-02-28 2011-04-13 弗吉尼亚大学专利基金会 血清素转运体基因与酗酒的治疗
US20100260844A1 (en) 2008-11-03 2010-10-14 Scicinski Jan J Oral pharmaceutical dosage forms
IL278149B2 (en) 2010-07-02 2024-03-01 Univ Virginia Patent Foundation A molecular genetic approach to the treatment and diagnosis of alcohol and drug dependence
CA2848211A1 (en) 2011-09-09 2013-03-14 University Of Virginia Patent Foundation Molecular genetic approach to treatment and diagnosis of alcohol and drug dependence
RU2476209C1 (ru) * 2012-02-29 2013-02-27 Станислав Анатольевич Кедик Имплантируемое лекарственное средство на основе налтрексона для лечения пациентов, зависимых от алкоголя или опиатов
US9572885B2 (en) 2013-03-15 2017-02-21 Durect Corporation Compositions with a rheological modifier to reduce dissolution variability
GB201308440D0 (en) * 2013-05-10 2013-06-19 Dalgleish Angus Therapeutic
WO2023023038A1 (en) * 2021-08-17 2023-02-23 Yale University Treatment compositions and methods

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH11505547A (ja) * 1996-03-13 1999-05-21 エール ユニバーシティ ナルトレキソン及び関連化合物を用いる禁煙処置

Also Published As

Publication number Publication date
BR9909138A (pt) 2000-12-05
KR20010034678A (ko) 2001-04-25
HK1032542A1 (en) 2001-07-27
SK284623B6 (sk) 2005-08-04
RU2226107C2 (ru) 2004-03-27
PL193241B1 (pl) 2007-01-31
CA2325739A1 (en) 1999-09-30
PL343069A1 (en) 2001-07-30
HUP0101546A3 (en) 2002-10-28
DE69904922D1 (de) 2003-02-20
CA2325739C (en) 2007-05-15
HUP0101546A2 (hu) 2001-09-28
SK14282000A3 (sk) 2001-05-10
EP0945133A1 (en) 1999-09-29
ATE230993T1 (de) 2003-02-15
NO20004788D0 (no) 2000-09-25
CZ296367B6 (cs) 2006-02-15
AU3522699A (en) 1999-10-18
HU226555B1 (en) 2009-03-30
US6512009B1 (en) 2003-01-28
NO20004788L (no) 2000-11-24
AU758569B2 (en) 2003-03-27
EP1063995B1 (en) 2003-01-15
CZ20003525A3 (cs) 2001-04-11
DE69904922T2 (de) 2004-01-08
NO319313B1 (no) 2005-07-11
WO1999048500A1 (en) 1999-09-30
DK1063995T3 (da) 2003-03-10
EP1063995A1 (en) 2001-01-03

Similar Documents

Publication Publication Date Title
ES2190205T3 (es) Combinacion para el tratamiento de la dependencia del alcohol que contiene un antagonista opioide y un modulador del complejo receptor de nmda.
CO5011096A1 (es) Medicamentos que contienen antagonistas del receptor 5-ht3 para el tratamiento de la ibs
DE69808130T2 (de) Adamantan-derivate
EE200000320A (et) Uudsed ühendid
AR033555A1 (es) Producto para el tratamiento del carcinoma de receptor de estrogeno positivo, y uso de dicho producto para preparar medicamentos
BR0112311A (pt) Compostos e composições para liberar agentes ativos, forma de dosagem unitária, método para preparar ditas composições e seu uso
GT199700009A (es) Terapia combinada para la osteoporosis.
AR020442A1 (es) Agonistas de 5ht2serotonergicos para el tratamiento de glaucoma
AR035500A1 (es) Uso de clorpromazina y pentamidina para la fabricacion de medicamentos, composicion farmaceutica y paquete farmaceutico que comprenden clorpromazina y pentamidina.
CL2008001920A1 (es) Composicion farmaceutica que comprende un inhibidor de la pde 2, un agonista del receptor selectivo e2 y un portador; y uso en el tratamiento de fractura y/o defecto oseo (div. sol. 3179-04).
CL2009001279A1 (es) Compuestos derivados de nociceptina; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento del dolor (sol. divisional 2103-03).
ES2149044T3 (es) Metanosulfonato de paroxetina.
CL2009001899A1 (es) Composicion farmaceutica que comprende: i) un antagonista del receptor de at1 o una sal, ii) un sensibilizante a la insulina o una sal y iii) un vehiculo farmaceuticamente aceptable; uso para la prevencion, demora de progreso o tratamiento de hipertension, diabetes, entre otras (div. sol. 2034-01).
AR025052A1 (es) Derivados de 2-dialquilaminoalquilbifenilo sustituidos, procedimiento para su preparacion, medicamentos que contienen estos compuestos y el uso de estoscompuestos para la preparacion de medicamentos.
AR026968A1 (es) Una tableta matriz que permite la liberacion prolongada de trimetazidina lluego de su administracion por via oral
AR034813A1 (es) Composiciones farmaceuticas y uso de las mismas
AR025330A1 (es) Combinacion de sustancias activas con clonidina
CR6398A (es) Antagonistas de 5ht1 para terapia antidepresiva
AR024232A1 (es) Bromhidrato de eletriptan monohidratado, composicion farmaceutica, su uso en la preparacion de medicamentos y procedimiento para su preparacion
UY26376A1 (es) Combinaciones sinteticas de un antagonista de nk1 y un analogo estructural de gaba
CL2002001701A1 (es) Uso de al menos un compuesto seleccionado entre melatonina, agentes melatoninergicos, agonistas y antagonistas de melatonina, en una cantidad de 0,0025-50 mg, para preparar un medicamento util para el tratamiento y mejora de la calidad repadora del sueno.
BR9812404A (pt) Combinação de um antagonista de endotelina, preparação farmacêutica, processo para preparar uma preparação farmacêutica, e , uso de uma combinação de um bloqueador de beta receptor e de um antagonista de endotelina
ES2175661T3 (es) Derivados de la isoflavona, procedimientos para la preparacion de los mismos y composiciones farmaceuticas que los contienen.
ES2173294T3 (es) Nuevo uso medico.
AR043016A2 (es) Un compuesto antimigranico eletriptan y composicion farmaceutica que lo contiene